Can You Take Alprazolam with Pregabalin?

Severity assessment

Major. The co-administration of alprazolam and pregabalin carries a major risk of severe central nervous system (CNS) depression, including profound sedation and life-threatening respiratory depression.

Mechanism (plain English)

Both alprazolam and pregabalin work by affecting chemical messengers in the brain that calm nerve activity. Alprazolam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity, leading to sedative and anxiolytic effects. Pregabalin, a gabapentinoid, binds to a specific part of calcium channels in the brain, which reduces the release of several neurotransmitters, including those involved in pain and anxiety. When taken together, their combined actions lead to an additive depressant effect on the brain, slowing down vital functions like breathing and consciousness. This can result in excessive drowsiness, confusion, and dangerously suppressed breathing.

Evidence level

Regulator-flagged. This interaction is highlighted by regulatory bodies such as the MHRA and is supported by clinical guidelines like the BNF, which explicitly warn about the additive CNS depressant effects of these drug classes.

Top regulator advisories (cite verbatim or close paraphrase)

• TGA (Australia): No specific public advisory found for the exact pair of alprazolam and pregabalin. However, the TGA has investigated reports of misuse, abuse, and dependence associated with pregabalin and gabapentin, and separately for benzodiazepines, indicating a general concern for these drug classes. The product information for alprazolam (e.g., XANAX) and pregabalin (e.g., LYRICA) generally warns about CNS depressant effects and interactions with other CNS depressants.
• MHRA / NICE (UK): The MHRA has reviewed warnings regarding addiction, dependence, withdrawal, and tolerance for gabapentinoids (including pregabalin) and benzodiazepines (including alprazolam). The BNF states that both pregabalin and alprazolam have effects on the CNS and can cause sedation, which might affect the ability to perform skilled tasks. The MHRA has also issued advisories on pregabalin regarding reports of severe respiratory depression, particularly when co-administered with other CNS depressants.
• FDA / CDC (US): The FDA prescribing information for alprazolam (XANAX) states that benzodiazepines produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistamines, ethanol, and other drugs that produce CNS depression. The FDA prescribing information for pregabalin (LYRICA) warns that it may cause dizziness and somnolence and impair patients’ ability to drive or operate machinery. While not a specific advisory for the pair, the general warnings for each drug regarding CNS depression are applicable.
• EMA (Europe): No specific EMA guideline or advisory for the exact pair of alprazolam and pregabalin was readily found. However, EMA product information for both drugs generally includes warnings about CNS depression and interactions with other CNS depressants, consistent with other regulatory bodies.

Clinical risk factors that elevate the danger

• Elderly patients: Increased sensitivity to CNS depressant effects and reduced drug clearance.
• Patients with respiratory compromise: Pre-existing conditions like COPD or sleep apnea increase the risk of severe respiratory depression.
• Concomitant use of other CNS depressants: Alcohol, opioids, antihistamines, or other sedatives significantly amplify the depressant effects.
• High doses of either medication: Dose-dependent increase in CNS depression.
• Rapid dose escalation: Increases the risk of adverse effects before tolerance can develop.
• Impaired renal or hepatic function: Can lead to increased drug levels and prolonged effects.

What a patient should be told

• Risk: Taking alprazolam and pregabalin together can make you very drowsy, confused, and can dangerously slow down your breathing. This combination can be life-threatening.
• Do not stop suddenly: Never stop taking these medications suddenly without talking to your doctor or pharmacist first, as this can lead to serious withdrawal symptoms, including seizures.
• Warning signs: Be aware of warning signs such as extreme drowsiness, difficulty waking up, slow or shallow breathing, unusual dizziness, or confusion. If you experience these, seek immediate medical attention.
• Safer alternatives: Discuss with your doctor or pharmacist if there are safer alternative treatments or if your doses need to be adjusted to minimize risks.
• Urgent care triggers: If you or someone with you experiences severe difficulty breathing, unresponsiveness, or extreme sedation, call emergency services immediately.

Top 3 sources (with full citation)

1. NICE. Pregabalin | Interactions | BNF. National Institute for Health and Care Excellence. Available at: https://bnf.nice.org.uk/interactions/pregabalin/ (Accessed: June 1, 2026).
2. MHRA. Improving information supplied with gabapentinoids (pregabalin/gabapentin), benzodiazepines and Z-drugs. Medicines and Healthcare products Regulatory Agency. January 8, 2026. Available at: https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs (Accessed: June 1, 2026).
3. FDA. XANAX (alprazolam) tablets, USP CIV. U.S. Food and Drug Administration. 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018276s045lbl.pdf (Accessed: June 1, 2026).

Notes for the reviewing pharmacist

The primary concern with alprazolam and pregabalin co-administration is additive CNS depression, leading to profound sedation and respiratory depression. While neither drug directly inhibits or induces the metabolism of the other in a significant pharmacokinetic interaction, their pharmacodynamic interaction is highly significant. Misconceptions may arise from patients assuming that because both are prescribed for anxiety or pain, they are interchangeable or safe to combine. Emphasize the importance of patient education regarding the risks of additive CNS depression, especially with concomitant use of other sedatives or alcohol. Particular attention should be paid to elderly patients and those with pre-existing respiratory conditions, who are at higher risk for severe adverse outcomes. Gradual tapering is crucial if discontinuation is necessary to avoid withdrawal symptoms.

Source metadata JSON

{
  "pair": "alprazolam + pregabalin",
  "severity": "Major",
  "evidence_level": "Regulator-flagged",
  "source_urls": "https://bnf.nice.org.uk/interactions/pregabalin/;https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs;https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018276s045lbl.pdf"
}